Relapsing-Remitting Multiple Sclerosis Clinical Trial
Official title:
Effects of Electromechanical Gait Trainer on Endurance, Fatigue and Daily Life Autonomy in Patients With Multiple Sclerosis: a Randomized Control Trial
Multiple Sclerosis is a very disabling disorder in young adult patients leading to an important limitation in daily life activities and social participation. Among of the different causes of disability in MS patients gait impairments, fatigue and balance disorders can be considered as the main concerns. Thus, gait restoration in patients with MS is the one of the primary objective of rehabilitation and often influences whether a patient can return home or to work. Even if potentially innovative treatments like treadmill training have been proposed, nowadays the role of robotic assisted locomotion rehabilitation has not been extensively studied in patients with MS.
Background Multiple sclerosis (MS) is the most common chronic disabling disease of the
central nervous system in young adults. Gait disorders represent one of the greatest causes
of disability in patients with MS. Thus, gait restoration in patients with MS is the one of
the primary objective of rehabilitation and often influences whether a patient can return
home or to work.
Despite significant progress in the development of disease-modifying drugs, pharmacologic
therapy alone does not warrant optimal care in MS. Exercise has been recognized as a
feasible form of self-management for persons with the disease. Regular exercise can improve
daily activity, cardiovascular fitness, muscle strength, health perception, and reduce
fatigue in patients with MS.
To restore gait, modern concepts of rehabilitation support a repetitive task-specific
approach. In recent years it has also been shown that higher intensities of walking practice
(resulting in more repetitions trained) result in better outcomes for patients after stroke.
Recently, the introduction of robotic devices for gait rehabilitation have showed to be a
feasible approach in order to improve gait ability in patients with stroke and spinal cord
lesions. These devices allow to train patients under a graduated body weight support
condition and to guide the patient's steps reproducing a physiologic gait pattern for as
long as the clinical conditions allow. This activity can be executed requiring only
supervision by a physiotherapist and in absolutely safety condition for the patient.
Repetitive locomotor training is an innovative approach in gait disturbances in patients
with multiple sclerosis. Only scant data on this issue is available and all these studies
have been performed by means of conventional physiotherapy or treadmill training approaches.
Nowadays the effectiveness of robotic devices for gait rehabilitation has not yet been
evaluated in patients with multiple sclerosis.
Aim of the study The aim of the study is to evaluate the effect of a repetitive locomotor
training by electromechanical gait trainer on gait endurance, fatigue and activities daily
life in patients with MS.
Study Design Randomised controlled, blinded clinical trial. Materials and methods Fifty
patients with definite diagnosis of MS according to McDonald criteria, and with EDSS score
equal to or below 7 will be enrolled in the study. Patients with disease recurrence that
worsens significantly during the 8 weeks before recruitment will be excluded. At the moment
of recruitment (before treatment), at the end of treatment (6 weeks) and one month after the
end of the treatment (FU) each patient will be tested with the following clinical and
instrumental procedures. Clinical assessment procedures: 6-minute Walking Test, 10-meter
Walking Test, Fatigue Severity Scale, Multiple Sclerosis Quality Of Life-54, Hamilton Rating
Scale for Depression, Falls Efficacy Scale. Instrumental assessment procedures: GAITRite®
System, Stabilometric Assessment and measure of energy cost by COSMED K4b2.
As primary outcome measure will be considered the 6-minute Walking Distance Test. As
secondary outcomes measures will be considered the 10-meter Walking Test, Fatigue Severity
Scale and the Multiple Sclerosis Quality Of Life-54, Hamilton Rating Scale for Depression,
Falls Efficacy Scale, Spatio-temporal parameter with GAITRite® System, Stabilometric
Assessment and measure of energy cost by COSMED K4b2. The allocation in the two groups will
be done with simple randomisation.
Patients will be randomized into two groups. The first group (experimental group) will be
subjected to 12 treatment session (2 sessions/week) on Gait Trainer machine. The second
group (control group) will undergo to a conventional treatment with the same duration and
frequency of the experimental group. Data will be analysed by means parametric and
non-parametric tests. Both, within and between groups comparison will be performed. Data
will be analyzed using SPSS software (ver 11.0; SPSS Inc., Chicago, IL, USA). Expected
results: we could hypothesize that the training performed by the experimental group could
improve gait endurance and daily life disability in patients with MS.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
| Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
| Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
| Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
| Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
| Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
| Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
| Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
| Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
| Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
| Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
| Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|